ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
Based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated significant improvement in both progression-free survival and overall survival...









